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Postnatal exposure to a progestin does not prevent uterine 
adenogenesis in domestic dogs
Tamara Ponchon†, Mariana Lopez Merlo†, Marcela Faya, Marcelo Priotto, Claudio Barbeito, Cristina Gobello*
Laboratory of Reproductive Physiology, Faculty of Veterinary Medicine, National University of La Plata, Buenos Aires B 1900 AVW, Argentina
To assess the effects of a single supraphysiological postnatal administration of a progestogen on uterine glands in dogs, 10 females were 
randomly assigned to a medroxyprogesterone acetate 35 mg (MPA; n = 6) or placebo (n = 4) group within the first 24 h of birth. The safety 
of the treatment was also evaluated. A transient mild clitoris enlargement appeared in MPA-treated females. Microscopic postpubertal uterine 
assessment revealed the presence of uterine glands in all cases without significant differences in the area occupied by the glands per m2 of 
endometrium nor in the height of the uterine epithelium.
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In both precocial and altricial mammals such as mice, rats, 
sheep and pigs, uterine adenogenesis begins during the first 2 
weeks of postnatal life [1,5]. Specifically, canine adenogenesis 
is initiated by the end of postnatal week 1 and both epithelial and 
stromal cell proliferation patterns decrease systematically over 
time, such that endometrial gland development is essentially 
completed by week 6 to 8 [2]. 
In previous studies carried out in sheep [9] and mice [3], 
neonatal administration of progestins permanently inhibited the 
genesis of uterine glands causing adult infertility. Although 
abundant international reports [3,6] support investigation of the 
potential use of neonatal progestins in small animal permanent 
contraception, a preliminary report showed that a progestogen 
(medroxyprogesterone acetate 10 mg/kg every 3 weeks) did not 
inhibit uterine adenogenesis when serially administered up to 
the age of 6 months [10]. In this respect, it has been shown that 
there is a limited time window of susceptibility to 
progestin-mediated inhibition of gland development and that 
administration outside this period leads to a failure of complete 
or permanent abolishment of adenogenesis [3]. Furthermore, a 
protocol including eight progestin injections would be 
impractical and unsafe [8].
Based on previous reports, it was hypothesized that a single 
supraphysiological progestin administered before the onset of 
uterine adenogenesis permanently abolishes gland 
development in domestic canids. Thus, the goal of the present 
study was to assess the effects of a single postnatal 
administration of medroxyprogesterone acetate on postpubertal 
uterine glands in dogs. The clinical safety of this treatment was 
also evaluated. 
Ten cross-bred, female littermates born in our institutional 
colony were sexed and identified at birth. The study was 
reviewed and approved by the Animal Care and Use Committee 
of the Veterinary School of the National University of La Plata 
and all experiments were conducted under the guidelines 
established in The Guide for The Care and Use of Laboratory 
Animals, USA.
Puppies (333.2 ± 17.3 g body weight) were randomly 
assigned to one of the following treatment groups within the 
first 24 h of birth: medroxyprogesterone acetate (MPA) 35 mg 
subcutaneously (s.c.; n = 6; Singestar; Laboratories Konig, 
Argentina) or placebo (PLC) : 0.6 mL corn oil s.c. (n = 4). 
All animals were followed up until the first pubertal signs 
appeared. During the follow up period, they were observed for 
sexual behavior, physically examined and weighed. Eventual 
appearance of clinical side effects was also recoded. Vaginal 
cytology was carried out three times per week from the fourth 
month of age onwards. Puberty was defined by finding more 
than 80% superficial keratinized cells and a clean background 
in the vaginal smears accompanied by typical estrous behavior.
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Fig. 1. Uterus of female dogs treated postnatally with 
medroxyprogesterone acetate 10 mg/100 g subcutaneously (s.c) 
(A) or Placebo s.c. (B) and hysterectomized after pubertal estrous
cycle. Notice normal uterine gland pattern in both treatments. 
*Stroma. †Glandular epithelium. H&E stain. Scale bars = 20 m.
Table 1. Physical and histological parameters (mean ± SEM) of 
puppies treated postnatally with medroxyprogesterone acetate 
(MPA; n = 6) or Placebo (PLC; n = 4)
Parameter MPA PLC
*Age at puberty (wk) 42.5 ± 2 38.5 ± 2
*Weight at puberty (kg) 18.8 ± 1 18.5 ± 0
*Uterine glands/m2 0.27 ± 0 0.21 ± 0
**Height of the uterine epithelium (m) 15.4 ± 1 13.2 ± 1
No significant differences between groups. *p ＞ 0.1, **p ＞ 0.05.
As the female dogs attained puberty, peripheral blood 
samples were taken 14 days after estrus for ovulation 
assessment (progesterone ＞ 5 ng/mL; Elecsys; Roche 
Diagnostics, Germany), after which all the bitches underwent 
ovariohysterectomy. 
After surgical removal, the uteri were macroscopically 
examined, weighed, and internally inspected. Cross-sections of 
each uterine horn were fixed and processed for histological 
evaluation. The uteri were examined for the presence or 
absence of endometrial glands. The area occupied by uterine 
glands per m2 of endometrium over the total area of each 
microscope field was measured by planimetry. The height of the 
uterine epithelium was assessed by counting 100 cells in a total 
of 10 images per uterus taken with a 20× objective.
Differences between groups were carried out by Fisher’s 
Exact and Student’s t tests. Data were expressed as mean ± SEM 
and p values ＜ 0.05 were considered significant.
Age and body weight at puberty did not differ between groups 
(Table 1). The MPA-treated bitches presented mild clitoris 
enlargement from 2 to 17 postnatal weeks, after which they 
gradually normalized. All pubertal females showed normal 
sexual behavior, ovulated during heat and presented no side 
effects. 
Uterine wet weight was not different between groups and its 
gross internal evaluation revealed no abnormalities. 
Microscopic assessment of the uteri showed the presence of 
uterine glands in all the cases. In the MPA-treated dogs, the area 
occupied by uterine glands per m2 of endometrium and the 
height of the uterine epithelium did not differ from the PLC 
group (Table 1, panels A and B in Fig. 1). 
This is the first study that describes the effect of a single 
postnatal supraphysiological dose of a potent and time -released 
progestin, medroxyprogesterone acetate, on canine uterine 
adenogenesis. This progestin treatment did not seem to affect 
somatic development or age at puberty. The transient clitoris 
abnormalities observed in MPA- treated females could be due to 
the androgenic effect of progestins [7]. Converse to what has 
been reported for the neonatal administration of other steroids 
in rodents [11], in this study, progestin did not modify sexual 
behavior. The hypothalamic-pituitary-ovarian axis functionality 
was apparently not affected as ovulation occurred in all the 
animals. 
Histological assessment examination revealed that the single 
supraphysiologic dose of the long term release progestin did not 
prevent the genesis of uterine glands in these bitches. It is 
difficult to interpret these findings in contraposition to what has 
been extensively described for ewes and mice [3,6]. 
Interestingly, similar treatments have also failed to block 
uterine adenogenesis in porcine species [4]. In these dogs 
neither the area occupied by uterine glands nor the height of the 
uterine epithelium was reduced by the progestin. Furthermore, 
epithelium height had a tendency to be higher in the MPA group.
Although, this pharmacological protocol appeared to be 
clinically safe, there is still the potential for eventual long term 
side effects. Nevertheless, a single postnatal supraphysiological 
dose of medroxyprogesterone acetate did not ablate uterine 
adenogenesis or cause short or medium term side effects in 
domestic dogs. 
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